GUCY2C/Guanylyl cyclase C[Biotin], His & Avi, Human
GUCY2C/Guanylyl Cyclase C[Biotin], His & Avi, Human

Immobilized Anti-GUCY2C Antibody, hFc Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for GUCY2C/Guanylyl cyclase C[Biotin], His & Avi, Human with the EC50 of 30.6 ng/ml determined by ELISA.

GUCY2C/Guanylyl Cyclase C[Biotin], His & Avi, Human

The purity of GUCY2C/Guanylyl cyclase C[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC.

GUCY2C/Guanylyl Cyclase C[Biotin], His & Avi, Human

Biotinylated GUCY2C/Guanylyl cyclase C[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

GUCY2C/Guanylyl cyclase C[Biotin], His & Avi, Human

Guanylyl cyclase C (GUCY2C) has canonical centrality in defense of key intestinal homeostatic mechanisms, encompassing fluid and electrolyte balance, epithelial dynamics, antitumorigenesis, and intestinal barrier function. GUCY2C may represent a new target for anti-obesity pharmacotherapy.
Z03913
¥121,253.00

Ask us a question
Product Introduction
Species Human
Protein Construction
GUCY2C/Guanylyl cyclase C (Ser24-Gln430)
Accession # P25092-1		 His Avi
N-term C-term
Conjugate Biotin
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 48.8 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 55-65 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from a 0.22 μm filtered solution in PBS, pH 7.4.
Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O more than 100 μg/ml.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • GUCY2C/Guanylyl Cyclase C[Biotin], His & Avi, Human
    • GUCY2C/Guanylyl Cyclase C[Biotin], His & Avi, Human

    Immobilized Anti-GUCY2C Antibody, hFc Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for GUCY2C/Guanylyl cyclase C[Biotin], His & Avi, Human with the EC50 of 30.6 ng/ml determined by ELISA.

  • GUCY2C/Guanylyl Cyclase C[Biotin], His & Avi, Human
    • GUCY2C/Guanylyl Cyclase C[Biotin], His & Avi, Human

    The purity of GUCY2C/Guanylyl cyclase C[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC.

  • GUCY2C/Guanylyl Cyclase C[Biotin], His & Avi, Human
    • GUCY2C/Guanylyl Cyclase C[Biotin], His & Avi, Human

    Biotinylated GUCY2C/Guanylyl cyclase C[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Guanylyl cyclase C (GUCY2C) has canonical centrality in defense of key intestinal homeostatic mechanisms, encompassing fluid and electrolyte balance, epithelial dynamics, antitumorigenesis, and intestinal barrier function. GUCY2C may represent a new target for anti-obesity pharmacotherapy.
Synonyms Guanylyl cyclase C; GC-C; STAR; GUCY2C; GUC2C; STA receptor; DIAR6; EC 4.6.1; GCC; GUC2CEC 4.6.1.2; MUCIL

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.